The document summarizes the Indian pharmaceutical industry. It states that India has the 3rd largest pharmaceutical industry by volume and 6th largest by size, accounting for 2.4% of the global market. The domestic demand in India is close to $36.8 billion and is expected to continue growing at a CAGR of 13% over the next 5 years. 90% of drugs sold in India are estimated to be generics. The key strengths of the Indian pharmaceutical industry are fair intellectual property protection, a strong manufacturing base, and low production costs. Major players in the industry include Sun Pharma, Abbott, Cipla, Cadila, and others. The industry is regulated through coordinated efforts between central and state governments. Not
Africa pharmaceutical market, industry analysis, forecast 2024aarktech2018
The report covers the present ground scenario and the future growth prospects of Africa Pharmaceuticals Market. Furthermore, it includes statistics of Branded and Generic Drugs along with the details of ongoing projects in the pharma sector in Africa.
East African Pharmaceutical Sector: Opportunities and ChallengesPharmaAfrica
Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Africa pharmaceutical market, industry analysis, forecast 2024aarktech2018
The report covers the present ground scenario and the future growth prospects of Africa Pharmaceuticals Market. Furthermore, it includes statistics of Branded and Generic Drugs along with the details of ongoing projects in the pharma sector in Africa.
East African Pharmaceutical Sector: Opportunities and ChallengesPharmaAfrica
Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Presentation by NEPAD Agency on the African Medicines Regulatory Harmonisation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
China Pharmaceutical Market : SWOT Analysis, Government policies, Business an...Maria Robert
Purchase a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=17129.
Pharmaceutical Industry in China – Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges report presented by Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS) & by Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Key success factors to win in MENA pharmaceutical market, Market access planning, creating value, major challenges and changes in Pharmaceutical culture in MENA
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Presentation by NEPAD Agency on the African Medicines Regulatory Harmonisation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
China Pharmaceutical Market : SWOT Analysis, Government policies, Business an...Maria Robert
Purchase a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=17129.
Pharmaceutical Industry in China – Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges report presented by Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS) & by Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Key success factors to win in MENA pharmaceutical market, Market access planning, creating value, major challenges and changes in Pharmaceutical culture in MENA
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Granules India is our typical Multibagger stock, but a Stock
which is a Good Investment due to the enormous growth
opportunities due to increasing capacity and It has a
differentiated business model which will deliver superior
returns in the long run.
Core Investment Thesis :
The company is in pharma space which has been growing at a
fast clip due to rising generics in the developed world as
governments globally are trying to cut healthcare cost. The
company has been a strong player in the API segment with
good pricing power in the commoditized market.
All matters relating to NPPA including its functions of price control and monitoring.
Responsible for development of infrastructure, manpower and skills for the pharmaceutical sector.
Work for the promotion and coordination of basic, applied and other research in areas related to the pharmaceutical sector and for international co-operation in pharmaceutical research.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
What is the "Drugs (Prices Control) Order (DPCO)" ? The Drugs Prices Control Order, 1995 is an order issued by the Government of India under Sec. 3 of Essential Commodities Act, 1955 to regulate the prices of drugs.
HPAPI DS/DP Manufacturing - Industry TrendsDrReddysCPS
HPAPI DS/DP manufacturing - trends in the pharma industry, a presentation delivered at Informex 2015 by CPS' Dr. Aaron Heiss, Senior Technology Manager.
Polyhydroxyalkanoate are linear polyesters that are produced from fermentation of lipid or sugar by bacteria. The rising demand for biodegradable materials, increase in oil prices and policies concerning green procurement are the driving factors for investment by companies in this market.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
1. SHANKAR R 14114
GEORGE JACOB 14095
DIVYA LIZ GEORGE 14093
DHARA B SHAH 14067
MARY MONISHA 14060
G5
INDIAN PHARMACEUTICAL INDUSTRY
Committed to a healthier
life
2. Indian Pharmaceuticals
World’s 3rd largest [volume]
6th largest market globally [size]
2.4% of the Global Pharma Industry
Domestic demand [2014-15] close to $36.8 billion
cCAGR 13%, to continue for the next 5 years
90% of drugs sold estimated to be generics
1
3. KEY STRENGTHS
Fair protection of intellectual property rights
Strong manufacturing base.
Drug prices 1/10th of international price and 40 % cheaper to set up plants.
60-70% cheaper for bulk drug production.
Highly trained pool of scientists and professionals.
Highest quality approvals from USFDA
Growing biotechnology industry.
Low labour cost
2
14. Growth drivers
Demand Side
Drivers
Policy Support
Supply Side
Drivers
Cost advantage
Manufacturing hub
546 sites registered
Penetration of chemists
Accessibility to improve
Health insurance
Stress related disease
Diagnostic facilities
Reduction in approval
time
Pharma education
Accessibility for BPL
Exemptions
10
15. Key challenges
Drug Quality, not adhering to cGMP
Clinical trial quality
Low margin of profits due to Govt pricing policy – Drug price control order
Patent issues
Low input for R & D
USFDA checks
11
16. Opportunities
$44 billion lose due to patent expiry in US
Expansion of Biosimilars and Bio-pharmaceuticals.
Growth of CRAMS
NMITLI & DPRP schemes
Fiscal incentives to R &D units
12
17. India’s share in anda approvals
370
398
433
418 421
442
499
380 379
59
21%
28%
29% 30% 31%
35%
40%
43%
34%
41%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
0
100
200
300
400
500
600
2006 2007 2008 2009 2010 2011 2012 2013 2014 YTD 2015
Total Approvals India as a % of total approvals
13
18. BIOSIMILAR : THE next big thing
Active
Ingredients
sourced
from living
organisms
Sensitive to
storage and
handling
Approval –
Multi step
process
Complex
nature –
Not easily
copied
USD 1.4
billion by
2016
Overall
market
sales – 20%
growth
Cadila
Biocon
Dr Reddy’s
Lupin
WockhardtCadila’s
Exemptia,
biosilmilar
of Humira
14
3rd largest pharmaceuticals market by 2020.
20% of global exports in generics.
USD 45 Billion in revenue by 2020.
USD 26.1 Billion in generics by 2016.
USD 200 Billion to be spent on infrastructure by 2024.
49% of all drug master filings registered in the USA
The Drugs and Cosmetics Act, 1940 (Drugs Act) and Drugs and Cosmetic Rules, 1945 (Drug rules) regulate the
import, manufacture, distribution and sale of drugs in India. Under the provisions of these Acts, the Centre appoints
the Drugs Technical Advisory Board (DTAB) to advise the central government and the state governments on
technical matters.
The responsibility to enforce the Drugs Act is entrusted with both the central government and the respective state
governments. Under the Drugs and Cosmetics Act, state authorities are responsible for regulating the manufacturing,
sale and distribution of drugs, whereas the central authorities are responsible for approving new drugs and clinical
trials, laying down the standards for drugs, controlling the quality of imported drugs and coordinating
the activities of
state drug control organisations.
The Drugs Controller General of India (DCGI) is the central body that coordinates
the activities of state drug control
organisations, formulates policies and ensures uniform implementation of the Drugs Act throughout India. It is also
responsible for approval of licenses of specified categories of drugs, such as blood and blood products, IV Fluids,
Vaccine and Sera.
Indian pharmaceuticals industry is mainly regulated on the basis of patents, price and quality
Source: CRISIL
Patents
Before 2005, the regulatory system in India focused only on process patents. Indian pharmaceutical companies
thrived during the process patent regime. They would reengineer
products of global innovator companies, which were
unavailable in India, and launch them in the country as generics, as India did not recognise the product patents. In
this manner, Indian companies gained process chemistry skills, but did not focus on R&D for new drug discovery.
In January 2005, India complied with the World Trade Organisation (WTO) to follow the product patent regime [sale of
reengineered
products (for drugs patented after 1995) is restricted]. However, enterprises, which had made
significant investments and were producing and marketing the concerned product prior to January 1, 2005 and which
continue to manufacture the product covered by the patent on the date of grant of the patent, are protected, and the
patentee cannot institute infringement suits against them, but would be entitled to reasonable royalty.
For a detailed analysis on the product patent regime and its impact, please refer to the Thematic Coverage section.
Drug prices
The Drug Price Control Order (DPCO) fixes the ceiling price of some APIs and formulations. APIs and formulations
falling under the purview of the legislation are called scheduled drugs and scheduled formulations. The National
Pharmaceutical Pricing Authority (NPPA) collects data and studies the pricing structure of APIs and formulations and accordingly makes recommendations to the Ministry of Chemicals and Fertilisers.
The new Pharmaceutical Policy, notified in 2012, intends to bring 348 essential drugs in the National List of Essential
Medicines (NLEM), under the purview of the DPCO. With this policy, the market size of drugs under price control will
increase from 1520
per cent of the domestic formulations market to 2030
per cent. The policy also introduces a
radical change in the mechanism of control: shifting from the current costbased
control to a marketbased
price
mechanism.
Under the policy, the ceiling price for each drug under control would be fixed as the simple average price of brands
having more than 1 per cent market share (by value) in the sales (MAT Moving
Annual Turnover) of that particular
molecule. Thus, prices of brands which are higher than this ceiling will need to be lowered. The ceiling prices will be
allowed an annual increase as per the Wholesale Price Index (WPI). Prices will be recalculated using MAT only once
in five years or when the NLEM is updated.
Price of drugs that were part of the earlier policy, but do not come under the current policy, would be frozen for a year
and, thereafter, allowed a maximum annual increase of 10 per cent. A 10 per cent increase would also be the limit for
prices of drugs outside the government's price control.
Quality
No drug can be imported, manufactured, stocked, sold or distributed in India unless it meets the quality standards
laid down in the Drugs Act. All companies have to comply with Schedule M of the Act, which outlines various
requirements for manufacturing drugs and pharmaceuticals by applying cGMP (current Good Manufacturing Practice).
cGMP has to be followed for control and management of manufacturing and quality control testing of drugs.